{
  "api_version": "1",
  "request": {
    "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Chemotherapeutic+Agent&page=6",
    "query": {
      "intervention": "Chemotherapeutic Agent",
      "page": 6
    },
    "page_size": 10
  },
  "pagination": {
    "page": 6,
    "page_size": 10,
    "total_count": 599,
    "total_pages": 60,
    "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Chemotherapeutic+Agent&page=7&page_size=10",
    "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Chemotherapeutic+Agent&page=5&page_size=10"
  },
  "source": "remote",
  "last_synced_at": "2026-10-13T12:09:45.179Z",
  "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.",
  "notes": [
    "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.",
    "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.",
    "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees."
  ],
  "trials": [
    {
      "nct_id": "NCT00245037",
      "title": "Busulfan, Fludarabine, and Total-Body Irradiation in Treating Patients Who Are Undergoing a Donor Stem Cell Transplant for Hematologic Cancer",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1",
        "PHASE2"
      ],
      "conditions": [
        "Chronic Myeloproliferative Disorders",
        "Leukemia",
        "Lymphoma",
        "Multiple Myeloma and Plasma Cell Neoplasm",
        "Myelodysplastic Syndromes",
        "Myelodysplastic/Myeloproliferative Neoplasms",
        "Precancerous Condition"
      ],
      "interventions": [
        {
          "name": "therapeutic allogeneic lymphocytes",
          "type": "BIOLOGICAL"
        },
        {
          "name": "busulfan",
          "type": "DRUG"
        },
        {
          "name": "cyclosporine",
          "type": "DRUG"
        },
        {
          "name": "fludarabine phosphate",
          "type": "DRUG"
        },
        {
          "name": "mycophenolate mofetil",
          "type": "DRUG"
        },
        {
          "name": "peripheral blood stem cell transplantation",
          "type": "PROCEDURE"
        },
        {
          "name": "Total Body Irradiation (TBI)",
          "type": "RADIATION"
        },
        {
          "name": "Granulocyte colony-stimulating factor (G-CSF)",
          "type": "DRUG"
        },
        {
          "name": "Phenytoin",
          "type": "DRUG"
        },
        {
          "name": "Methotrexate",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL",
        "DRUG",
        "PROCEDURE",
        "RADIATION"
      ],
      "sponsor": "OHSU Knight Cancer Institute",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "80 Years",
        "sex": "ALL",
        "summary": "18 Years to 80 Years"
      },
      "enrollment_count": 147,
      "start_date": "2005-06",
      "completion_date": "2015-08",
      "has_results": true,
      "last_update_posted_date": "2017-09-27",
      "last_synced_at": "2026-10-13T12:09:45.179Z",
      "location_count": 1,
      "location_summary": "Portland, Oregon",
      "locations": [
        {
          "city": "Portland",
          "state": "Oregon"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00245037"
    },
    {
      "nct_id": "NCT00775645",
      "title": "S0715: Acetyl-L-Carnitine in Preventing Neuropathy in Women With Stage I, II, or IIIA Breast Cancer Undergoing Chemo",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Breast Cancer",
        "Chemotherapeutic Agent Toxicity",
        "Fatigue",
        "Neuropathy",
        "Neurotoxicity"
      ],
      "interventions": [
        {
          "name": "acetyl-L-carnitine hydrochloride",
          "type": "DIETARY_SUPPLEMENT"
        },
        {
          "name": "placebo",
          "type": "OTHER"
        }
      ],
      "intervention_types": [
        "DIETARY_SUPPLEMENT",
        "OTHER"
      ],
      "sponsor": "SWOG Cancer Research Network",
      "sponsor_class": "NETWORK",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "120 Years",
        "sex": "FEMALE",
        "summary": "18 Years to 120 Years · Female only"
      },
      "enrollment_count": 437,
      "start_date": "2009-09",
      "completion_date": "2013-06",
      "has_results": true,
      "last_update_posted_date": "2017-08-14",
      "last_synced_at": "2026-10-13T12:09:45.179Z",
      "location_count": 295,
      "location_summary": "Mobile, Alabama • Anchorage, Alaska • Fairbanks, Alaska + 196 more",
      "locations": [
        {
          "city": "Mobile",
          "state": "Alabama"
        },
        {
          "city": "Anchorage",
          "state": "Alaska"
        },
        {
          "city": "Anchorage",
          "state": "Alaska"
        },
        {
          "city": "Fairbanks",
          "state": "Alaska"
        },
        {
          "city": "Antioch",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00775645"
    },
    {
      "nct_id": "NCT03742102",
      "title": "A Study of Novel Anti-cancer Agents in Patients With Metastatic Triple Negative Breast Cancer",
      "overall_status": "ACTIVE_NOT_RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1",
        "PHASE2"
      ],
      "conditions": [
        "Triple Negative Breast Neoplasms"
      ],
      "interventions": [
        {
          "name": "Durvalumab",
          "type": "DRUG"
        },
        {
          "name": "Capivasertib",
          "type": "DRUG"
        },
        {
          "name": "Oleclumab",
          "type": "DRUG"
        },
        {
          "name": "Paclitaxel",
          "type": "DRUG"
        },
        {
          "name": "Trastuzumab deruxtecan",
          "type": "DRUG"
        },
        {
          "name": "Datopotamab deruxtecan",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "AstraZeneca",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "130 Years",
        "sex": "FEMALE",
        "summary": "18 Years to 130 Years · Female only"
      },
      "enrollment_count": 243,
      "start_date": "2018-12-21",
      "completion_date": "2027-02-26",
      "has_results": true,
      "last_update_posted_date": "2026-08-04",
      "last_synced_at": "2026-10-13T12:09:45.179Z",
      "location_count": 8,
      "location_summary": "Tucson, Arizona • Columbia, Maryland • Boston, Massachusetts + 4 more",
      "locations": [
        {
          "city": "Tucson",
          "state": "Arizona"
        },
        {
          "city": "Columbia",
          "state": "Maryland"
        },
        {
          "city": "Boston",
          "state": "Massachusetts"
        },
        {
          "city": "Boston",
          "state": "Massachusetts"
        },
        {
          "city": "Grand Rapids",
          "state": "Michigan"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03742102"
    },
    {
      "nct_id": "NCT02083653",
      "title": "Sym004 vs Standard of Care in Subjects With Metastatic Colorectal Cancer",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Metastatic Colorectal Cancer"
      ],
      "interventions": [
        {
          "name": "Sym004 (12 mg/kg)",
          "type": "DRUG"
        },
        {
          "name": "Sym004 (9/6 mg/kg)",
          "type": "DRUG"
        },
        {
          "name": "Best Supportive Care (BSC)",
          "type": "OTHER"
        },
        {
          "name": "Fluorouracil (5-FU)",
          "type": "DRUG"
        },
        {
          "name": "Capecitabine",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG",
        "OTHER"
      ],
      "sponsor": "Symphogen A/S",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 254,
      "start_date": "2014-03-06",
      "completion_date": "2017-04-26",
      "has_results": true,
      "last_update_posted_date": "2019-04-16",
      "last_synced_at": "2026-10-13T12:09:45.179Z",
      "location_count": 9,
      "location_summary": "Los Angeles, California • San Diego, California • Fort Myers, Florida + 6 more",
      "locations": [
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "San Diego",
          "state": "California"
        },
        {
          "city": "Fort Myers",
          "state": "Florida"
        },
        {
          "city": "Port Saint Lucie",
          "state": "Florida"
        },
        {
          "city": "St. Petersburg",
          "state": "Florida"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02083653"
    },
    {
      "nct_id": "NCT06900595",
      "title": "Testing the Addition of an Anti-Cancer Drug, Cabozantinib to the Immunotherapy Drug Cemiplimab (REGN2810), in Adolescents and Adults With Advanced Adrenocortical Cancer",
      "overall_status": "RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Locally Advanced Adrenal Cortical Carcinoma",
        "Metastatic Adrenal Cortical Carcinoma",
        "Recurrent Adrenal Cortical Carcinoma",
        "Stage III Adrenal Cortical Carcinoma AJCC v8",
        "Stage IV Adrenal Cortical Carcinoma AJCC v8",
        "Unresectable Adrenal Cortical Carcinoma"
      ],
      "interventions": [
        {
          "name": "Biospecimen Collection",
          "type": "PROCEDURE"
        },
        {
          "name": "Cabozantinib",
          "type": "DRUG"
        },
        {
          "name": "Cemiplimab",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Computed Tomography",
          "type": "PROCEDURE"
        },
        {
          "name": "Magnetic Resonance Imaging",
          "type": "PROCEDURE"
        }
      ],
      "intervention_types": [
        "PROCEDURE",
        "DRUG",
        "BIOLOGICAL"
      ],
      "sponsor": "National Cancer Institute (NCI)",
      "sponsor_class": "NIH",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "12 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "12 Years and older"
      },
      "enrollment_count": 48,
      "start_date": "2026-02-22",
      "completion_date": "2029-06-02",
      "has_results": false,
      "last_update_posted_date": "2026-09-18",
      "last_synced_at": "2026-10-13T12:09:45.179Z",
      "location_count": 81,
      "location_summary": "Phoenix, Arizona • La Jolla, California • Madera, California + 60 more",
      "locations": [
        {
          "city": "Phoenix",
          "state": "Arizona"
        },
        {
          "city": "La Jolla",
          "state": "California"
        },
        {
          "city": "Madera",
          "state": "California"
        },
        {
          "city": "Aurora",
          "state": "Colorado"
        },
        {
          "city": "Jacksonville",
          "state": "Florida"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT06900595"
    },
    {
      "nct_id": "NCT06463028",
      "title": "Sapanisertib and Serabelisib (PIKTOR) With Paclitaxel and a Substudy With an Insulin-Suppressing Diet in Patients With Advanced/Recurrent Endometrial Cancer",
      "overall_status": "RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Endometrial Cancer"
      ],
      "interventions": [
        {
          "name": "Sapanisertib",
          "type": "DRUG"
        },
        {
          "name": "Serabelisib",
          "type": "DRUG"
        },
        {
          "name": "Paclitaxel",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Faeth Therapeutics",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "FEMALE",
        "summary": "18 Years and older · Female only"
      },
      "enrollment_count": 40,
      "start_date": "2024-12-12",
      "completion_date": "2029-09",
      "has_results": false,
      "last_update_posted_date": "2025-12-24",
      "last_synced_at": "2026-10-13T12:09:45.179Z",
      "location_count": 18,
      "location_summary": "La Jolla, California • San Francisco, California • Miami Beach, Florida + 15 more",
      "locations": [
        {
          "city": "La Jolla",
          "state": "California"
        },
        {
          "city": "San Francisco",
          "state": "California"
        },
        {
          "city": "Miami Beach",
          "state": "Florida"
        },
        {
          "city": "St. Petersburg",
          "state": "Florida"
        },
        {
          "city": "West Palm Beach",
          "state": "Florida"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT06463028"
    },
    {
      "nct_id": "NCT04164082",
      "title": "Testing the Addition of an Anti-cancer Drug, Pembrolizumab, to the Usual Intravesical Chemotherapy Treatment (Gemcitabine) for the Treatment of BCG-Unresponsive Non-muscle Invasive Bladder Cancer",
      "overall_status": "ACTIVE_NOT_RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Bladder Flat Urothelial Carcinoma In Situ",
        "Non-Muscle Invasive Bladder Urothelial Carcinoma",
        "Stage 0a Bladder Cancer AJCC v8",
        "Stage 0is Bladder Cancer AJCC v8",
        "Stage I Bladder Cancer AJCC v8"
      ],
      "interventions": [
        {
          "name": "Biopsy Procedure",
          "type": "PROCEDURE"
        },
        {
          "name": "Biospecimen Collection",
          "type": "PROCEDURE"
        },
        {
          "name": "Computed Tomography",
          "type": "PROCEDURE"
        },
        {
          "name": "Cystoscopy",
          "type": "PROCEDURE"
        },
        {
          "name": "Gemcitabine Hydrochloride",
          "type": "DRUG"
        },
        {
          "name": "Magnetic Resonance Imaging",
          "type": "PROCEDURE"
        },
        {
          "name": "Pembrolizumab",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Transurethral Resection of Bladder Tumor",
          "type": "PROCEDURE"
        }
      ],
      "intervention_types": [
        "PROCEDURE",
        "DRUG",
        "BIOLOGICAL"
      ],
      "sponsor": "National Cancer Institute (NCI)",
      "sponsor_class": "NIH",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 161,
      "start_date": "2020-03-18",
      "completion_date": "2026-12-09",
      "has_results": false,
      "last_update_posted_date": "2026-08-11",
      "last_synced_at": "2026-10-13T12:09:45.179Z",
      "location_count": 381,
      "location_summary": "Birmingham, Alabama • Anchorage, Alaska • Fairbanks, Alaska + 257 more",
      "locations": [
        {
          "city": "Birmingham",
          "state": "Alabama"
        },
        {
          "city": "Anchorage",
          "state": "Alaska"
        },
        {
          "city": "Anchorage",
          "state": "Alaska"
        },
        {
          "city": "Anchorage",
          "state": "Alaska"
        },
        {
          "city": "Anchorage",
          "state": "Alaska"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04164082"
    },
    {
      "nct_id": "NCT02998268",
      "title": "Study of Pembrolizumab in Locally Advanced Esophageal Adenocarcinoma",
      "overall_status": "ACTIVE_NOT_RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Esophageal Adenocarcinoma"
      ],
      "interventions": [
        {
          "name": "Pembrolizumab",
          "type": "DRUG"
        },
        {
          "name": "Taxol",
          "type": "DRUG"
        },
        {
          "name": "Carboplatin",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Weill Medical College of Cornell University",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "99 Years",
        "sex": "ALL",
        "summary": "18 Years to 99 Years"
      },
      "enrollment_count": 42,
      "start_date": "2017-03-07",
      "completion_date": "2026-03",
      "has_results": true,
      "last_update_posted_date": "2026-03-17",
      "last_synced_at": "2026-10-13T12:09:45.179Z",
      "location_count": 4,
      "location_summary": "Los Angeles, California • Ann Arbor, Michigan • New York, New York + 1 more",
      "locations": [
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "Ann Arbor",
          "state": "Michigan"
        },
        {
          "city": "New York",
          "state": "New York"
        },
        {
          "city": "Providence",
          "state": "Rhode Island"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02998268"
    },
    {
      "nct_id": "NCT07204340",
      "title": "TLN-372 in Advanced KRAS Mutant Solid Tumors",
      "overall_status": "RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "KRAS Mutant Solid Tumors"
      ],
      "interventions": [
        {
          "name": "TLN-372",
          "type": "DRUG"
        },
        {
          "name": "TLN-372 in combination with cetuximab",
          "type": "DRUG"
        },
        {
          "name": "TLN-372 in combination with pembrolizumab",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Treeline Biosciences, Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 270,
      "start_date": "2025-09-29",
      "completion_date": "2032-04-01",
      "has_results": false,
      "last_update_posted_date": "2026-07-28",
      "last_synced_at": "2026-10-13T12:09:45.179Z",
      "location_count": 6,
      "location_summary": "Birmingham, Alabama • Boston, Massachusetts • Grand Rapids, Michigan + 3 more",
      "locations": [
        {
          "city": "Birmingham",
          "state": "Alabama"
        },
        {
          "city": "Boston",
          "state": "Massachusetts"
        },
        {
          "city": "Grand Rapids",
          "state": "Michigan"
        },
        {
          "city": "St Louis",
          "state": "Missouri"
        },
        {
          "city": "New York",
          "state": "New York"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT07204340"
    },
    {
      "nct_id": "NCT07811297",
      "title": "A Study of Catequentinib Hydrochloride (AL3818) in Endometrial, LGSOC, STS or GBM Cancers",
      "overall_status": "NOT_YET_RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1",
        "PHASE2"
      ],
      "conditions": [
        "Endometrial Neoplasms",
        "Ovarian Neoplasms",
        "Soft Tissue Sarcoma (STS)",
        "Glioblastoma"
      ],
      "interventions": [
        {
          "name": "AL58805",
          "type": "DRUG"
        },
        {
          "name": "AL3818",
          "type": "DRUG"
        },
        {
          "name": "Temozolomide (TMZ)",
          "type": "DRUG"
        },
        {
          "name": "CCNU",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Advenchen Pharmaceuticals, LLC.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 138,
      "start_date": "2026-09-01",
      "completion_date": "2031-09-01",
      "has_results": false,
      "last_update_posted_date": "2026-09-10",
      "last_synced_at": "2026-10-13T12:09:45.179Z",
      "location_count": 1,
      "location_summary": "Houston, Texas",
      "locations": [
        {
          "city": "Houston",
          "state": "Texas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT07811297"
    }
  ]
}